Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.

British journal of cancer - 1 Feb 2022

Pietrasz Daniel, Wang-Renault Shufang, Taieb Julien, Dahan Laetitia, Postel Mathilde, Durand-Labrunie Jerome, Le Malicot Karine, Mulot Claire, Rinaldi Yves, Phelip Jean-Marc, Doat Solene, Blons Hélène, de Reynies Aurelien, Bachet Jean-Baptiste, Taly Valérie, Laurent-Puig Pierre

Abstract excerpt

OBJECTIVE: The prognostication of metastatic pancreatic adenocarcinoma (mPDAC) patients remains uncertain, mainly based on carbohydrate antigen 19-9 (CA19-9), with limited utility. Circulating tumour DNA (ctDNA) has been suggested as a prognostic factor, but its added value has been poorly explored. The objective was to determine whether ctDNA is an independent factor for the prognostication of mPDAC. DESIGN:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to DNA Methylation

Share to Neoplasm Metastasis

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 34811505
DOI: 10.1038/s41416-021-01624-2
PMCID: PMC8810868

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.PMID 34811505Read ↗

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.Semantic proximity Read ↗

Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage.Semantic proximity Read ↗

Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging.Semantic proximity Read ↗

Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancerSemantic proximity Read ↗

Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasisSemantic proximity Read ↗

Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.Semantic proximity Read ↗

Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.Semantic proximity Read ↗

Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic CancerSemantic proximity Read ↗

Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.Semantic proximity Read ↗

Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.Semantic proximity Read ↗

Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.